|
|
|
Clinical Trial for Myxoid Liposarcoma (SMI-BRS-202)
Phase II, multicenter, open-label clinical trial designed to determine the efficacy and safety of brostallicin when administered once every 3 weeks in patients with myxoid liposarcoma with (12;16) translocation
The primary objective of this study is to determine the response rate following brostallicin administration.
What is brostallicin?
Brostallicin (bräst-al-iss-in) is a new class of
cancer drug — a synthetic DNA minor
groove binding agent. We are developing brostallicin
for the treatment of advanced
or metastatic soft tissue sarcoma. More
>>
How is this soft tissue sarcoma study conducted?
This myxoid liposarcoma study is a multicenter, open-label phase II trial.
Who can participate in this myxoid liposarcoma clinical trial?
The following criteria (along with other technical criteria) must be
evaluated by the study physician: |
| • |
Histologically confirmed myxoid liposarcoma |
|
• |
Patients with metastatic and/or unresectable myxoid liposarcoma that is progressive and standard curative measures do not exist or are no longer effective |
|
• |
Patient has measurable tumor on CT, spiral CT, or MRI scan that meet RECIST criteria |
| • |
Age ≥18 years |
| • |
Karnofsky performance status (KPS) ≥ 70% |
| • |
Life expectancy of at least 3 months |
| • |
Acceptable liver function |
| • |
Acceptable renal function |
| • |
Acceptable hematologic status |
This trial is being conducted in Santa Monica, CA. Details on the NIH Web site >
Posted March 18, 2008
Copyright © 2004-2008 Cell Therapeutics, Inc., Seattle,
WA, USA. All rights reserved. "Making cancer more treatable" is
a registered mark of CTI.
|
 |
